Figure 1

Progression-free and overall survival stratified by the baseline number of metastatic lesions (A), the baseline sum of the longest diameters of the target lesions (B), and maximum standardized uptake value (C). (A) Kaplan–Meier curves of Progression-free survival (PFS) and Overall survival (OS) stratified by the baseline number of metastatic lesions (BNML). Patients with BNML was one (N = 42) had significantly better PFS than those with BNML was more than one (N = 52) (6-months PFS: 55.0% [95% CI 38.2–69.0%] vs. 34.0% [95% CI 21.5–47.0%], p = 0.008). Patients with BNML was one (N = 42) had significantly better OS than those with BNML was more than one (N = 52) (1-year OS: 78.6% [95% CI 59.8–89.4%] vs. 47.0% [95% CI 31.5–60.9%], p = 0.002). (B) Kaplan–Meier curves of PFS and OS stratified by baseline sum of the longest diameters of the target lesions (BSLD). Patients with BSLD ≤ 28 mm (low, N = 33) had significantly better PFS than those with BSLD > 28 (high, N = 61) (6-months PFS: 62.6% [95% CI 43.5–76.8%] vs. 33.2% [95% CI 21.6–45.3%], p = 0.003). Patients with BSLD ≤ 28 mm (low, N = 33) had significantly better OS than those with BSLD > 28 (high, N = 61) (1-year OS: 86.9% [95% CI 63.7–95.7%] vs. 47.8% [95% CI 33.8–60.6%], p < 0.001). (C) Kaplan–Meier curves of PFS and OS stratified by maximum standardized uptake value (SUVmax) of PET. Patients with SUVmax ≤ 12.93 (low, N = 23) had significantly better PFS than those with SUVmax > 12.93 (high, N = 25) (6-months PFS: 59.2% [95% CI 35.9–76.5%] vs. 28.0% [95% CI 12.4–46.0%], p = 0.014). Patients with SUVmax ≤ 12.93 (low, N = 23) had significantly better OS than those with SUVmax > 12.93 (high, N = 25) (1-year OS: 75.0% [95% CI 49.7–88.9%] vs. 48.1% [95% CI 25.6–67.5%], p = 0.003).